Hansoh Pharma Wins China Breakthrough Therapy Status for Lung Cancer ADC Combo

Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) just unveiled an announcement.

Hansoh Pharmaceutical Group has announced that its self-developed B7-H3-targeted antibody-drug conjugate HS-20093, administered by injection in combination with adebrelimab, has been granted Breakthrough-Therapy-Designated Drug status by China’s National Medical Products Administration. The proposed indication is for patients with locally advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations whose disease has progressed or relapsed after platinum-based chemotherapy.

The Breakthrough-Therapy designation underscores Hansoh’s growing capabilities in innovative oncology treatments and may accelerate the clinical development and regulatory pathway for HS-20093 in combination therapy. This regulatory milestone could strengthen the company’s competitive position in China’s oncology market and offers potential new treatment options for a difficult-to-treat lung cancer population with limited targeted therapy choices.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$46.41 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

More about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited is a China-based pharmaceutical company focused on developing and commercializing innovative medicines. The group engages in research and development of advanced therapies, including antibody-drug conjugates, targeting major disease areas such as oncology for the domestic market and potentially broader regional use.

Average Trading Volume: 9,257,896

Technical Sentiment Signal: Buy

Current Market Cap: HK$238.6B

For detailed information about 3692 stock, go to TipRanks’ Stock Analysis page.